Company: ABBV
Filing Date: 2025-03-24
Form Type: DEF 14A
Source: 0001558370-25-003537
Chunk: 47

Company: AbbVie Inc.
Filing Date: 2025-03-24
Form: DEF 14A
Chunk 47
---
 | ​             | 1,711,768 | ​ | ​            |   872,716 | ​ | ​     | 10,303,536 |
| Executive Vice President, Chief |   |    ​ | ​ |        |         ​ | ​ | ​     | ​ | ​ | ​      |          ​ | ​ | ​      |         ​ | ​ | ​              |         ​ | ​ | ​             |         ​ | ​ | ​            |         ​ | ​ |       |          ​ |
| Human Resources Officer (7)     |   |    ​ | ​ |        |         ​ | ​ | ​     | ​ | ​ | ​      |          ​ | ​ | ​      |         ​ | ​ | ​              |         ​ | ​ | ​             |         ​ | ​ | ​            |         ​ | ​ |       |          ​ |

| (1) | In accordance with Securities and Exchange Commission (SEC) rules, the amounts in this column represent the aggregate grant date fair value of the awards determined in accordance with Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 718. AbbVie generally determines the grant date fair value of stock awards by multiplying the number of shares granted by the average of the high and low market prices of one share of AbbVie common stock on the award grant date. The grant date fair value of performance shares and performance-based restricted stock units is determined assuming target performance (the most probable outcome as of the grant date), and the value of the performance shares with a TSR market condition is determined using the Monte Carlo simulation model. Assuming the maximum level of performance conditions will be achieved for all performance shares and performance-based restricted stock units, the grant date fair values for Mr. Michael, Mr. Gonzalez, Mr. Reents, Mr. Stewart, Dr. Saleki-Gerhardt, and Mr. Richmond, would be $17,889,416, $33,896,645, $9,415,532, $11,674,930, $8,756,102, and $8,662,029, respectively. |

| (2) | In accordance with SEC rules, the amounts in this column represent the aggregate grant date fair value of the awards determined in accordance with FASB ASC Topic 718. These amounts were determined as of the option grant date using a Black-Scholes stock option valuation model. These amounts are being reported solely for the purpose of comparative disclosure in accordance